BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update

BioLineRx (BLRX) Tops Q1 EPS by 11c

May 26, 2021 7:06 AM EDT

BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.04), $0.11 better than the analyst estimate of ($0.15).

"Subsequent to the end of the first quarter, we were extremely excited to announce positive topline results from our GENESIS Phase 3 trial of Motixafortide in stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients," stated Philip Serlin, Chief Executive Officer of BioLineRx. "The results demonstrated, with a high degree of statistical significance, a... More